Durvalumab was approved by the U.S. Food and Drug Administration (FDA) in May 2017 to treat late-stage bladder cancer. It is approved specifically to treat urothelial carcinomas when they cannot be removed by surgery and have recurred after chemotherapy.
Clinical trials have tested the drug on patients with mesothelioma, lung cancer, melanoma, pancreatic cancer, gastric cancer, head and neck cancer, esophageal cancer, lymphoma, myelodysplastic syndrome and solid tumors.
The best results in these trials occurred in lung cancer patients.
A phase III clinical trial of durvalumab for stage 3 lung cancer patients reported the drug stopped tumor growth for an average of 11 months. Some patients showed no new tumor growth after chemotherapy and radiation therapy.
In July 2017, the FDA designated durvalumab as a breakthrough therapy, which expedites the development and review of the drug. In February 2018, the FDA approved Durvalumab for lung cancer treatment.
Promising results in lung cancer patients led to clinical trials testing durvalumab in the mesothelioma population.
In 2015, an Italian phase II trial began testing durvalumab in combination with tremelimumab on mesothelioma patients who did not qualify for surgery.
Around 62 percent of participants responded to durvalumab and tremelimumab, but the study failed to improve survival. Doctors leading the study said more research is necessary.
Several clinical trials in the U.S. and abroad are evaluating the effects of durvalumab in people with mesothelioma.
How Does Durvalumab Work?
Durvalumab — like the immunotherapy drug Keytruda — is a checkpoint inhibitor that blocks PD-L1.
PD-L1 is a protein on the surface of cancer cells that works like a mask to hide cancer from the immune system.
Durvalumab blocks PD-L1 and essentially removes the mask so the immune system can identify and attack cancer cells.
|Alternate Names||ImFinzi, MEDI4736|
|Drug Class||Checkpoint inhibitor, monoclonal antibody|
|Interacting Drug||Vaccines, vitamin E, zinc, cat’s claw, echinacea|
|Medical Studies||A Phase 2 Study of durvalumab in Combination with Tremelimumab in Malignant Pleural Mesothelioma|
|FDA Warning||Pneumonitis, liver disease, colitis, kidney inflammation, endocrine gland disease, infection, infusion reactions, fetal harm|
Find Immunotherapy Clinical Trials
Learn how to access mesothelioma clinical trials for immunotherapy.Sign Up Now
Durvalumab Side Effects
Durvalumab stimulates the immune system and may cause it to attack healthy organs and tissues. Side effects range from mild to severe.
Mild side effects include:
- Bone and muscle pain
- Loss of appetite
- Swelling in arms or legs
- Urinary tract infection
- Abdominal pain
Other mild side effects include reduced sodium in the blood and low white blood cell count.
Serious side effects of durvalumab include:
- Liver disease
- Inflammation in the lungs
- Kidney problems
- Inflammation of the colon lining
- Difficulty breathing
- Skin problems (rash, itching and blisters)
- Infusion-related reactions
- Damage to hormone glands (thyroid, adrenals, pituitary and pancreas)
Signs of severe infusion reactions include chills or shaking, flushing, itching or rash, wheezing or shortness of breath, fever, dizziness or lightheadedness, facial swelling and back or neck pain.
Talk to your doctor immediately if you notice any mild or serious side effects. Seek medical treatment quickly to keep side effects under control.
Research on Durvalumab in Mesothelioma Treatment
Nearly all clinical trials of durvalumab involving mesothelioma patients are too new to produce results.
Only the Italian study that began in 2015 has published early results, which proved the drug was effective against mesothelioma but did not improve survival.
Other clinical trials began in 2016 and 2017:
- In 2016, the Lung Institute at Baylor College of Medicine in Houston opened a trial that combines durvalumab with the immunotherapy drug tremelimumab. Participants in this trial, which is overseen by mesothelioma expert Dr. David Surgarbaker, must qualify for surgery.
- Dana-Farber Cancer Institute in Boston began a phase II clinical trial in April 2017 that combines durvalumab and tremelimumab among patients who do not qualify for mesothelioma surgery.
- A nationwide phase II trial began in June 2017 that combines durvalumab with chemotherapy as a first-line treatment for mesothelioma patients who do not qualify for surgery. The Seattle Cancer Care Alliance, a renowned mesothelioma treatment center, is participating in the trial.
Mesothelioma survivor and Navy veteran Jim McWhorter participated in Dana-Farber’s durvalumab clinical trial, and he initially responded well. His cancer stopped growing for several months. Then a CT scan showed the cancer was growing again, and McWhorter had to leave the trial in search of other options.
Research shows durvalumab works for many people with mesothelioma, but usually only for a period of time. Durvalumab may not be a cure for mesothelioma, but research is underway to investigate the roles it might play in controlling the cancer and improving survival.
12 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Hirschler, B., & Grover, D. (2017, May 1). AtraZeneca immunotherapy wins first approval in bladder cancer.
Retrieved from: https://www.reuters.com/article/us-astrazeneca-fda/astrazeneca-immunotherapy-wins-first-approval-in-bladder-cancer-idUSKBN17X22Y
National Cancer Institute. (2017, August 10). Durvalumab.
Retrieved from: https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab
Medscape. (n.d.). Durvalumab (Rx).
Retrieved from: https://reference.medscape.com/drug/imfinzi-durvalumab-1000145
Medline Plus. (2017, July 15). Durvalumab injection.
Retrieved from: https://medlineplus.gov/druginfo/meds/a617030.html
AstraZeneca. (2017, September 8).AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress.
Retrieved from: https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html
AstraZeneca. (2017, October 17). US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer.
Retrieved from: https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html
Calabro, L. et al. (2017). Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study.
Retrieved from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8558
FDA. (n.d.). Highlights of prescribing information: Imfinzi.
Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf#page=19
ClinicalTrials.gov. (2018, January 19). A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma.
Retrieved from: https://www.clinicaltrials.gov/ct2/show/NCT03075527
ClinicalTrials.gov. (2015, October 27). A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1).
Retrieved from: https://www.clinicaltrials.gov/ct2/show/NCT02588131
AstraZeneca.com. (2016, February 29). AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma.
Retrieved from: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html
- Antonia, S., Goldberg, S., et al. (2016, February 5). Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicenter, phase I b study. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/26858122
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified September 28, 2020